Plain-English translation of NCT07464912 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called can help treat idiopathic pulmonary fibrosis, a serious lung disease where tissue gradually becomes scarred and stiff. About 500 people will take either or a placebo (a dummy pill with no active ingredient) once daily for at least a year. Researchers want to see if this medication can slow disease progression and help people breathe better.
Idiopathic pulmonary fibrosis is a serious condition with limited treatment options, and doctors need new ways to help patients. This trial exists to find out whether this medication can work safely and effectively for people living with this disease.
You likely qualify if…
You likely don't qualify if…
You will go through a screening period (up to 4 weeks) where doctors confirm your IPF diagnosis with imaging tests. If you qualify, you'll be randomly assigned to take either the new medication or a placebo once daily by mouth for at least 52 weeks. You'll have regular clinic visits to check how you're doing, undergo breathing tests, and provide medical information so researchers can track whether the treatment is working and is safe.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China